文献类型：期刊文献

英文题名：Sorafenib Resistance in Hepatocellular Carcinoma: Emerging Molecular Insights from Long Non-Coding RNAs

作者：Jia, Dengke[1,2,3];He, Yaping[4];Chen, Qianle[1,2,3];Wu, Hao[1,2,3];Zhang, Yawu[1,2,3]

第一作者：Jia, Dengke

通信作者：Zhang, YW[1];Zhang, YW[2];Zhang, YW[3]

机构：[1]Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Peoples R China;[2]Lanzhou Univ, Hosp 2, Hepatobiliarypancreat Inst, Lanzhou 730000, Peoples R China;[3]Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Peoples R China;[4]Gansu Univ Chinese Med, Clin Coll Tradit Chinese Med, Lanzhou 730000, Peoples R China

第一机构：Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Peoples R China;[2]corresponding author), Lanzhou Univ, Hosp 2, Hepatobiliarypancreat Inst, Lanzhou 730000, Peoples R China;[3]corresponding author), Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Peoples R China.

年份：2025

外文期刊名：CURRENT PHARMACEUTICAL DESIGN

收录：;Scopus(收录号：2-s2.0-105012837122);WOS:【SCI-EXPANDED(收录号:WOS:001545179800001)】；

基金：This study was financed by the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (Grant No. CY2021-MS-B18 to YW Zhang).

语种：英文

外文关键词：Long non-coding RNAs; microRNAs; hepatocellular carcinoma; sorafenib; drug resistance; biomolecular marker

摘要：Background Sorafenib is a first-line treatment for patients with advanced hepatocellular carcinoma (HCC), but its clinical efficacy is often compromised by the acquisition of drug resistance. Various cancers, including HCC, are affected by long non-coding RNA (lncRNA), but the mechanisms underlying HCC sorafenib resistance have not been extensively studied. This article aims to summarize the recently reported pathways associated with sorafenib resistance and discusses potential applications for the treatment of HCC.Methods Relevant studies on the resistance of HCC to anti-tumor drugs were retrieved from PubMed. Given the compelling evidence that sorafenib is an effective treatment for advanced HCC, we analyzed the research papers on lncRNA and sorafenib resistance in HCC in the PubMed system in the past decade and found that lncRNA may be involved in sorafenib resistance in HCC through multiple pathways.Results lncRNA is widely involved in the resistance mechanism of HCC to sorafenib. Recent studies have revealed that numerous lncRNAs, such as NEAT1, affect the sensitivity of HCC to sorafenib through various mechanisms, including autophagy and AKT signaling pathways.Conclusion lncRNAs play a pivotal role in modulating HCC resistance to sorafenib. And lncRNA is expected to become a new solution to the resistance of sorafenib and other targeted drugs.